NOVEL SCREEN FOR TRANSLATION INHIBITORY ANTIFUNGALS

Information

  • Research Project
  • 2073188
  • ApplicationId
    2073188
  • Core Project Number
    R43AI036730
  • Full Project Number
    1R43AI036730-01
  • Serial Number
    36730
  • FOA Number
    RFA-PH-S9-2S
  • Sub Project Id
  • Project Start Date
    8/1/1994 - 30 years ago
  • Project End Date
    1/31/1995 - 30 years ago
  • Program Officer Name
  • Budget Start Date
    8/1/1994 - 30 years ago
  • Budget End Date
    1/31/1995 - 30 years ago
  • Fiscal Year
    1994
  • Support Year
    1
  • Suffix
  • Award Notice Date
    7/25/1994 - 30 years ago
Organizations

NOVEL SCREEN FOR TRANSLATION INHIBITORY ANTIFUNGALS

Fungal pathogens are responsible for a variety of diseases ranging from innocuous dermal mycoses to life-threatening systemic infections. In recent years the number of serious fungal infections has increased markedly as a result of the growing number of immunosuppressed and immunocompromised individuals, such as AIDS patients, transplant recipients, and chemotherapy or radiotherapy patients. Efficacious and non-toxic antifungal therapeutics are difficult to identify, in part due to the fact that both humans and fungi are eukaryotes and share many potential molecular targets in common. Most antifungals currently used act against a limited number of targets found primarily on the fungal cell surface. An urgent need exists for more antifungal agents, especially those acting against additional targets. Translation-targeted therapeutics are particularly desirable because of their proven value in treating bacterial infections. This proposal describes a novel high- throughput screen for identifying new antifungal agents specifically targeted against protein translation. The assay identifies translational inhibitors by their ability to stimulate the growth of a specially- designed test fungus on an indicator medium. Secondary assays are used to verify specificity for fungal translation and to determine toxicity to human cells. Preliminary results with purified compounds of known activity support the proposal.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    BM
  • Study Section Name
    Bacteriology and Mycology Subcommittee 1
  • Organization Name
    RIBOGENE, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    HAYWARD
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    94545
  • Organization District
    UNITED STATES